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after resection of recurrent GBM is a reasonably safe treat-
ment in patients aged >65 years. Seizures and systemic in-
fections may occur more frequently, but the trade-off is still 
favorable as survival may be influenced positively. Higher 
age should not be regarded as a contraindication for BCNU 
wafers.  © 2017 S. Karger AG, Basel 
 Introduction 
 Glioblastoma (GBM) is the most frequently occurring 
primary brain tumor. It is most likely to affect older pa-
tients, with the highest incidence between 65 and 84 years 
 [1] . The prognosis is dismal in any scenario, yet elderly 
patients have a particularly poor prognosis and often re-
quire treatment, which differs from the therapeutic stan-
dards in younger individuals  [2] . Gross total resection, 
whenever achievable, is the mainstay of surgical treat-
ment  [3] , while hypofractionated radiation therapy with 
40 Gy appears to be favorable compared to the 60-Gy reg-
imen recommended for younger patients  [4, 5] . As com-
bined radiochemotherapy seems to provide diminishing 
effects with increasing age, radiotherapy alone or chemo-
 Keywords 
 Glioblastoma · Carmustine · Bis-chloroethylnitrosourea · 
Wafers · Elderly · Chemotherapy 
 Abstract 
 Objective: To assess the safety and effectiveness of bis-chlo-
roethylnitrosourea (BCNU) wafers in elderly patients with re-
current glioblastoma (GBM).  Methods: Patients with recur-
rent GBM operated on between 2007 and 2014 were divided 
into 3 groups: >65 years with BCNU wafer implantation, >65 
years without BCNU wafer implantation, and  ≤ 65 years with 
BCNU wafer implantation. We compared survival and com-
plications.  Results: A total of 79 patients were identified: 24 
in the older BCNU group (median age 68.2 years, 33.3% with 
a methylated  MGMT promoter), 16 in the older non-BCNU 
group (median age 68.6 years, 31.3% with a methylated 
 MGMT promoter), and 39 in the younger BCNU group (me-
dian age 56.8 years). Survival after progression was 9.2 
months in the elderly BCNU group and 7.6 months in the el-
derly non-BCNU group ( p = 0.34); overall survival was 17.2 
and 15.9 months, respectively ( p = 0.35). We found a ten-
dency toward a higher rate of seizures and pneumonia in the 
older BCNU group.  Conclusion: BCNU wafer implantation 
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therapy alone may be advocated in elderly GBM patients 
 [6] . Currently, chemotherapy alone has been recom-
mended for elderly GBM patients (>65 years) with a 
methylated  MGMT promoter  [7] . However, the progno-
sis remains very poor, with a 1-year survival rate of 26.2% 
for patients aged 65–74 years and 11.0% for patients aged 
 ≥ 75 years  [8] . Hence, there is a strong need for new or 
additional therapeutic strategies in the treatment of el-
derly GBM patients to improve their survival.
 Bis-chloroethylnitrosourea (BCNU) was introduced 
in the form of wafers for local chemotherapy after resec-
tion of high-grade gliomas a quarter century ago  [9] . 
Since then, randomized controlled trials have demon-
strated increased overall survival (OS) in patients suffer-
ing from high-grade glioma both after implantation of 
BCNU wafers for recurrent tumor and after the initial 
diagnosis  [10–12] . The benefits of BCNU wafers have 
been consistently recognized in clinical trials, reviews, 
and meta-analyses  [13–15] . On the other hand, complica-
tions after BCNU wafer implantation have been repeat-
edly reported. Still, the addition of BCNU wafers to the 
therapeutic standard in GBM has become an established 
option.
 To date, the effectiveness of BCNU wafers in elderly 
patients has not been studied. Thus, we sought to com-
pare the survival and complication rates of patients with 
first recurrent GBM aged >65 years who had undergone 
BCNU wafer implantation intraoperatively as an adjunct 
therapy with those of elderly patients who had been treat-
ed for a first recurrent GBM without BCNU wafers. Ad-
ditionally, the complication rates of patients aged  ≤ 65 
years who had been treated with BCNU wafers were com-
pared with those of the older group who received BCNU 
wafers.
 Methods 
 We searched our tumor database for patients who had been 
diagnosed with a GBM between 2007 and 2014, had received tu-
mor resection both at diagnosis and after recurrence, with avail-
able magnetic resonance images, and in whom the  MGMT pro-
moter methylation status was known. The survival in patients >65 
years who had received BCNU wafer implantation at recurrence 
was compared with the survival in patients of the same age without 
local BCNU therapy. These groups were matched for factors as-
sociated with survival, including age, extent of resection, adjuvant 
treatment, and  MGMT promoter methylation status.
 In addition, to evaluate safety, patients aged  ≤ 65 years who had 
received BCNU wafers at surgery for recurrent tumor formed a 
control group for comparison of complication rates; individuals 
aged  ≤ 65 years who had not received BCNU wafers were not in-
cluded. The complications considered in our analysis were newly 
developed hydrocephalus, pseudocysts, cerebral abscess, increase 
in cerebral edema, pseudoprogression, deep vein thrombosis or 
pulmonary embolism, symptomatic increase in intracranial pres-
sure, systemic infection (e.g., pneumonia), seizures, cerebrospinal 
fluid leak, and wound healing disturbances. In case of missing in-
formation about the occurrence of complications, the respective 
patients were excluded from analysis of the complication in ques-
tion. Hence, for some items, the number of patients studied is low-
er than the total in their group. The study was approved by the 
local ethics committee (number EK179082004).
 For statistical evaluation, we performed a multivariate analysis 
which included age, sex,  MGMT promoter status, number of im-
planted wafers, extent of resection, and radiochemotherapy after 
first and after second surgery (yes or no) with log-rank test and 
Kaplan-Meier curves for survival analysis. Complications were 
compared with the Fisher exact test. OS was defined as the time 
from the first surgery until the last follow-up. Progression-free sur-
vival (PFS) was defined as PFS1 for the time between the first and 
second surgery and as PFS2 for the time between the second sur-
gery and the last follow-up.
 Results 
 Patient Population 
 We identified a total of 79 subjects: 24 patients aged 
>65 years (older BCNU group) who had undergone 
BCNU wafer implantation for their first recurrent GBM 
(17 male [70.8%], median age 68.2 years, range 65.3–76.6, 
8 with a methylated  MGMT promoter [33.3%], average 
number of wafers 5.9), 16 patients aged >65 years with a 
first recurrent GBM (older non-BCNU group) who had 
not received BCNU wafers (12 male [75.0%], median age 
68.6 years, range 65.7–81.9, 5 with a methylated  MGMT 
promoter [31.3%], average number of wafers 5.3), and 39 
patients aged  ≤ 65 years (younger BCNU group) who had 
been treated with BCNU wafers for recurrent GBM (25 
male [64.1%], median age 56.8 years, range 38.1–64.7). 
The Karnofsky performance score in all operated patients 
was  ≥ 70.
 All patients in the younger group ( ≤ 65 years), 91.7% 
of elderly patients with BCNU wafers, and 93.8% of el-
derly patients without BCNU wafers received systemic 
chemotherapy after the first tumor resection, with temo-
zolomide being by far the most commonly used drug. Ad-
juvant radiotherapy was applied to all younger patients, 
95.8% of elderly patients with BCNU, and 93.8% of el-
derly patients without BCNU. Complete tumor resection 
at first diagnosis was achieved in 56.4, 58.3, and 68.8% of 
patients in the younger BCNU, older BCNU, and older 
non-BCNU groups, respectively. Patients’ characteristics 
in all 3 groups are shown in  Table 1 .
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 Patients following BCNU wafer implantation were 
considered for systemic chemotherapy the same as pa-
tients without BCNU wafers. As there is no consensus on 
chemotherapy in the recurrent setting, the decision was 
made for each patient individually during interdisciplin-
ary tumor boards. Temozolomide was the most com-
monly used agent, while ACNU (nimustine), CCNU (lo-
mustine), bevacizumab, and irinotecan were used in few-
er cases, including combinations of agents. For an 
overview of the adjuvant treatments provided to elderly 
patients without BCNU wafer implantation, see  Table 2 .
 Comparison of Adverse Effects in Younger versus 
Elderly Patients with Wafer Implantation 
 One of 39 younger patients (2.6%) and 2 of 24 elderly 
patients (8.3%) with BCNU wafer implantation devel-
oped a hydrocephalus. Pseudocysts were not observed in 
any patient. One of the younger patients (2.6%) suffered 
from a cerebral abscess, while none of the elderly pa-
tients did. A general progression of postoperative cere-
bral edema occurred in 26 out of 36 younger patients 
(72.2%) and in 12 out of 22 elderly patients (54.5%). Two 
patients of each group (5.1 vs. 8.3%) developed a symp-
tomatic increase in intracranial pressure. Pseudopro-
gression was observed in 2 of 38 younger patients (5.3%) 
and 1 of 24 elderly patients (4.2%). Deep vein throm-
bosis or pulmonary embolism arose in 1 patient of the 
 Table 1.  Characteristics of the patients in each group
Patient characteristics ≤65 years 
with BCNU
>65 years 
with BCNU
>65 years 
without BCNU
p value 
between 
BCNU groups
p value 
between 
older groups
Number of patients 39 24 16
Males 25 (64.1%) 17 (70.8%) 12 (75.0%) 0.40a 0.53a
Median age, years 56.8 68.2 68.6 0.92b
Age range, years 38.1 – 64.7 65.3 – 76.6 65.7 – 81.9
MGMT promoter methylation 12 (30.8%) 8 (33.3%) 5 (31.3%) 0.52a 0.59a
Complete resection at first diagnosis 22 (56.4%) 14 (58.3%) 11 (68.8%) 0.49a 0.44a
Complete resection at first recurrence 19 (48.7%) 11 (45.8%) 10 (62.5%) 0.50a 0.28a
Mean number of BCNU wafers 5.9 5.3 0
Right tumor side 22 (56.4%) 10 (41.7%) 12 (75.0%) 0.27c 0.10c
Tumor localization
Frontal 13 (33.3%) 8 (33.3%) 4 (25.0%) 0.6a 0.42a
Temporal 10 (25.6%) 4 (16.7%) 5 (31.3%) 0.3a 0.24a
Parietal 2 (5.1%) 2 (8.3%) 1 (6.3%) 0.49a 0.65a
Occipital 5 (12.8%) 1 (4.2%) 1 (6.3%) 0.25a 0.64a
Involvement of two lobes 9 (23.1%) 9 (37.5%) 5 (31.3%) 0.17a 0.42a
 BCNU, bis-chloroethylnitrosourea. a One-sided Fisher exact test. b Two-sided Mann-Whitney U test. c Pearson χ2 test.
 Table 2. Adjuvant treatment of elderly patients without BCNU 
wafer implantation
MGMT 
promoter 
methylation
RT after 
first 
surgery
CT after 
first 
surgery
RT after 
second 
surgery
CT after 
second 
surgery
1 1 TMZ 0 ACNU/TMZ
1 1 TMZ 0 TMZ
0 1 TMZ 0 ACNU/TMZ
0 1 TMZ 0 0
0 1 TMZ 0 TMZ
0 1 TMZ 0 TMZ
0 1 TMZ 0 TMZ
1 1 TMZ 0 ACNU/TMZ/BV
0 1 TMZ 0 0
0 1 TMZ 0 0
0 1 TMZ 0 TMZ
1 1 TMZ 0 0
0 1 TMZ 1 TMZ
0 0 0 0 TMZ
1 1 TMZ 0 TMZ
0 1 TMZ 0 0
All but 1 patient (whose condition was deemed too bad for adjuvant 
treatment following a pulmonary embolism) received radiation and TMZ 
after the first surgery. After the second surgery, 1 patient underwent 
stereotactic radiotherapy. Most patients received chemotherapy after the 
second tumor resection, with TMZ being the most frequently used drug. 
ACNU, nimustine; BCNU, bis-chloroethylnitrosourea; BV, bevacizumab; 
CT, chemotherapy; RT, radiotherapy; TMZ, temozolomide.
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younger group (2.6%) and in 3 patients of the older 
group (12.5%). A cerebrospinal fluid leak developed in 3 
younger (7.7%) and 2 elderly patients (8.3%). Seven of 
the younger patients (17.9%) and 2 of the elderly patients 
(8.3%) experienced wound healing disturbances. None 
of these differences in complications yielded statistical 
significance. One of the younger patients (2.6%) and 4 of 
the elderly patients (16.7%) suffered from a systemic in-
fection, with a borderline statistical significance. None 
of the elderly patients treated without BCNU wafers de-
veloped systemic infections. Comparison of the rate of 
systemic infections between the groups >65 years with 
and without BCNU wafers yielded a nonsignificant re-
sult in the Fisher exact test. Seizures occurred in 2 of the 
younger (5.1%) and 5 of the older patients (20.8%), with 
a borderline statistical significance.  Table 3 provides an 
overview of the adverse effects related to BCNU wafer 
chemotherapy.
 Comparison of Survival in Patients  ≤ 65 Years with 
Wafer Implantation versus Patients >65 Years with 
Wafer Implantation 
 The younger BCNU-treated patients had a median 
PFS1 of 6.7 months (95% confidence interval [CI] 4.5–
8.8) after the first surgery, while the PFS1 was 7.4 months 
(95% CI 6.9–8.0) in the elderly BCNU group ( p = 0.41). 
Median PFS2 was 9.2 months (95% CI 5.8–12.6) in the 
younger group and 9.2 months (95% CI 7.5–10.9) in the 
older group ( p = 0.35). Mean OS was 19.0 months (95% 
CI 15.0–23.1) in the younger group and 17.2 months 
(95% CI 13.7–20.8) in the older group ( p = 0.41).
 Comparison of Survival in Patients >65 Years
with Wafer Implantation versus Patients >65 Years 
without Wafer Implantation 
 Patients in the older BCNU group (>65 years) had a 
median PFS1 of 7.4 months (95% CI 6.9–8.0) after the 
initial tumor resection compared with 10.4 months (95% 
CI 8.0–12.8) in older patients without BCNU ( p = 0.44). 
Median PFS2 was 9.2 months (95% CI 5.2–13.2) in the 
older BCNU group compared to 7.6 months (95% CI 2.8–
12.3) in the group without BCNU, but this was not sig-
nificant ( p = 0.34,  Fig. 1 ). The median OS was 17.2 months 
(95% CI 13.7–20.8) in the older BCNU group versus 15.9 
months (95% CI 13.0–18.8) in the non-BCNU group ( p = 
0.35,  Fig. 2 ).
 Comparison of Survival Depending on MGMT 
Methylation Status 
 The median OS in patients with an unmethylated 
 MGMT promoter was 18.7 months (95% CI 16.0–21.4) in 
the younger and 15.6 months (95% CI 11.1–20.2) in the 
older BCNU group ( p = 0.9). In patients with a methyl-
ated  MGMT promoter it was 21.7 months (95% CI 16.6–
26.8) and 18.3 months (95% CI 12.9–23.7), respectively
( p = 0.14).
 Comparing both groups aged >65 years, median OS 
after surgery with BCNU wafer implantation did not dif-
fer significantly, with 18.3 months (95% CI 12.9–23.7) in 
patients with a methylated  MGMT promoter versus 15.6 
months (95% CI 11.1–20.2) in those with an unmethyl-
ated  MGMT promoter ( p = 0.78).
 Table 3. Complications upon implantation of BCNU wafers for recurrent glioblastoma in patients ≤65 years (older BCNU group) and 
>65 years (younger BCNU group)
Complications Younger BCNU group Older BCNU group p value
Hydrocephalus 1/38 (2.6%) 2/22 (8.3%) 0.322
Pseudocysts 0/39 (0%) 0/24 (0%) –
Cerebral abscess 1/38 (2.6%) 0/22 (9%) 1
Progression of edema 26/36 (72.2%) 12/22 (54.5%) 0.255
Pseudoprogression 2/38 (5.3%) 1/24 (4.2%) 1
Deep vein thrombosis/pulmonary embolism 1/39 (2.6%) 3/24 (12.5%) 0.15
Symptomatic intracranial pressure increase 2/39 (5.1%) 2/24 (8.3%) 0.632
Systemic infections (e.g., pneumonia) 1/39 (2.6%) 4/24 (16.7%) 0.065
Seizures 2/39 (5.1%) 5/24 (20.8%) 0.095
Cerebrospinal fluid leak 3/39 (7.7%) 2/24 (8.3%) 1
Wound healing disturbances 7/39 (17.9%) 2/24 (8.3%) 0.462
The p values are given for the 2-sided Fisher exact test; the significance level was set at p = 0.05. BCNU, bis-chloroethylnitrosourea.
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 When considering patients aged >65 years without 
BCNU wafer implantation, the median OS was 15.9 
months (95% CI 13.0–18.7) in those with an unmethyl-
ated and 16.7 months (95% CI 11.7–21.7) in those with a 
methylated  MGMT promoter ( p = 0.80).
 Discussion 
 The concept of local delivery of BCNU wafer directly 
into a tumor resection cavity was developed in the 1990s 
and was approved in 2003 by the US Food and Drug Ad-
ministration as part of the management of patients with 
GBM. However, to date, data about the safety and the 
clinical effect of wafer implantation in patients aged >65 
years are lacking. Hence, the aim of our study was to ad-
dress these issues regarding safety following BCNU wafer 
implantation in elderly patients with recurrent GBM and 
to evaluate their effectiveness as an adjunct treatment op-
tion in the recurrent setting.
 Our study demonstrates a favorable adverse effect pro-
file of BCNU wafers in elderly patients when implanted 
for the treatment of recurrent GBM. The overall compli-
cation rate in the latter cohort was 66.7%, with postop-
erative progression of edema being by far the most com-
mon adverse effect; yet, interestingly, no complication 
was significantly more common when compared with el-
derly patients who did not receive BCNU wafers. Never-
theless, the comparison of BCNU-related complications 
in younger versus elderly patients demonstrated a slight-
ly higher rate of systemic infections (pneumonia) and sei-
zures in elderly patients as the only remarkable difference 
between both groups. However, the latter finding was not 
statistically significant.
 Of note, the complication rate in our study was some-
what lower than that reported by Subach et al.  [16] , who 
found complications in 76.6% of patients with recurrent 
GBM treated with BCNU wafers – mostly wound infec-
tions, sepsis, cerebrospinal fluid leak, and seizures. In a 
further study, Bock et al.  [17] reported a complication 
rate of 52% in a retrospective study of BCNU wafer im-
plantation for primary resection of high-grade glioma – 
mostly cerebral edema, healing abnormalities, cerebro-
spinal fluid leak, seizures, and alteration of mental status. 
New seizures developed in 16% of patients. Notably, in 
the large trials by Brem et al.  [10] and Westphal et al.  [12] , 
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>65 years with BCNU
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 Fig. 1. The survival after progression in patients aged >65 years 
who were implanted bis-chloroethylnitrosourea (BCNU) wafers at 
their surgery for recurrent glioblastoma was 9.2 months, com-
pared to 7.6 months in patients aged >65 years who did not receive 
BCNU wafers ( p = 0.34). 
 Fig. 2. The overall survival in patients aged >65 years who were 
implanted bis-chloroethylnitrosourea (BCNU) wafers at their sur-
gery for recurrent glioblastoma was 17.2 months, compared to 15.9 
months in patients aged >65 years who did not receive BCNU wa-
fers ( p = 0.35). 
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seizures were not more frequent among BCNU-treated 
patients than in the placebo groups.
 Considering the short survival time in GBM, especial-
ly in elderly patients, a possible higher risk of systemic 
infection (which can be sufficiently managed with antibi-
otics) and seizures (which can usually be controlled with 
medication) may be an acceptable trade-off for the chance 
of a slightly prolonged survival, as shown in our current 
analysis. Some considerable studies failed to detect a 
higher complication risk in patients treated with BCNU 
wafers  [15, 18] . With regard to treatment effectiveness, 
we could not determine a significant effect of the BCNU 
wafers on the survival of patients aged >65 years after im-
plantation in comparison to their counterparts who did 
not receive the wafers (PFS2 9.2 vs. 7.6 months). Although 
the difference in survival is not statically significant, these 
survival times are considerably longer than those in the 
literature, which are reported to be approximately 7 
months in a patient population with a median age of 56 
years  [19] . As patients aged >65 years who were not treat-
ed with BCNU wafers had a numerically higher rate of 
complete resection at surgery for recurrent GBM (62.5 vs. 
45.8%), yet a lower PFS2 than elderly patients with BCNU 
wafer implantation (7.6 vs. 9.2 months), we argue that the 
comparability of the groups may be flawed and that the 
positive effect of BCNU on survival may be underesti-
mated in our study.
 The 1.6-month improvement in median survival after 
implantation of BCNU wafers for first recurrent GBM 
and the 1.3-month improvement in OS in the older 
BCNU group over the control older non-BCNU group 
are roughly comparable with the available data, which 
showed an improvement in OS of 2–2.4 months  [10, 20] . 
Curiously, comparing survival data between the younger 
and the older BCNU group, there was no significant dif-
ference in OS (19.0 vs. 17.2 months), which might be ex-
plained by the fact that only patients in good condition 
(Karnofsky performance score  ≥ 70) underwent a second 
tumor resection with wafer implantation, independent of 
age. This may be a considerable factor blurring the differ-
ence in survival which would be expected with regard to 
age because the fraction of patients not receiving surgery 
upon tumor recurrence may have been much higher in 
the elderly group. Thus, we suspect a selection bias as the 
main reason for the lack of difference in survival after sur-
gery for recurrent GBM with BCNU wafer implantation 
between the younger and older patients.
 As expected, the median OS was numerically longer in 
patients with a methylated  MGMT promoter, although 
no statistical significance could be detected in our patient 
population. This observation held true both for patients 
with BCNU wafer implantation and those without. 
Hence, in this study, we cannot confirm an enhanced ef-
fect of BCNU wafers on survival in patients with  MGMT 
methylated tumors as has been suggested experimentally 
 [21] .
 From an economical perspective, BCNU wafer im-
plantation remains an expensive treatment. The cost of 
treatment in Germany depends on the number of placed 
wafers. The placement of 4–6 wafers costs around EUR 
7,564, whereas insertion of 7–9 wafers costs EUR 12,103 
[Veelken et al., unpublished data;  13 ]. Thus, the ques-
tion can be raised how high the monetary cost for a 
moderate increase in survival may be in socialized med-
icine. The same, however, goes for various other treat-
ments in oncology, chiefly immunotherapy and tumor-
treating fields. The latter yields a cost of USD 21,000 per 
month  [22] , while the total cost of a combination of ipi-
limumab and nivolumab for the treatment of melanoma 
has been reported to amount to USD 295,566 per patient 
 [23] . The question of the financial sustainability of these 
particularly expensive therapies is a question at the bor-
der between economics and ethics and will likely be ut-
tered more frequently and more explicitly in the near 
future.
 Our study has several limitations, starting with its ret-
rospective nature. As there was no randomization, there 
may have been differences between both elderly groups 
which we are not aware of. Furthermore, the patient pop-
ulation may be too small for detection of differences in 
survival and complication rates. In fact, OS, PFS2, and 
systemic infections as well as seizures were numerically 
considerably different between the groups, yet the differ-
ence did not reach statistical significance, which it might 
have done given a larger patient population.
 Of note, BCNU wafers were already in use before te-
mozolomide became the standard chemotherapeutic 
agent in GBM treatment. Skepticism about the concomi-
tant use of both drugs has been tempered by several stud-
ies and reviews demonstrating their compatibility  [24–
31] . In our study, we show that the combination of both 
agents – even in elderly patients – is a mostly safe option 
in the recurrent setting. It should be mentioned that we 
start adjuvant treatment with temozolomide 8 weeks after 
BCNU wafer implantation. This is the time at which the 
wafers have usually dissolved  [13, 32, 33] . This approach 
might minimize any side effects occurring due to simul-
taneous drug administration.
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 Conclusion 
 The use of BCNU implants after resection of recurrent 
GBM in the elderly is a reasonably safe and effective treat-
ment as long as patients present in good clinical condi-
tion. Seizures and systemic infections may be more likely 
upon use of BCNU wafers in this patient group. These 
possible complications need to be taken into account, but 
should not be the reason for not considering this treat-
ment option in elderly patients. Furthermore, survival 
may be increased in elderly patients with recurrent GBM 
when BCNU wafers are implanted upon second tumor 
resection. For detection of statistically significant correla-
tions, larger controlled studies are called for.
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